(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`(19) World Intellectual Property
`Organization
`International Bureau
`
`(43) International Publication Date
`7 March 2013 (07.03.2013)
`
`WIPO!IPCT
`
`\=
`
`(10) International Publication Number
`WO 2013/030218 Al
`
`GD)
`
`International Patent Classification:
`C07D 401/06 (2006.01)
`A6IP 19/00 (2006.01)
`C07D 409/14 (2006.01)
`A61P 37/00 (2006.01)
`AGLK 31/517 (2006.01)
`A6IP 9/00 (2006.01)
`A61P 35/00 (2006.01)
`A61P 31/00 (2006.01)
`A61IP 25/00 (2006.01)
`A6IP 3/00 (2006.01)
`
`(21)
`
`International Application Number:
`
`PCT/EP2012/066741
`
`(22)
`
`International Filing Date:
`
`29 August 2012 (29.08.2012)
`
`(25)
`
`(26)
`
`(30)
`
`(71)
`
`(72)
`(75)
`
`Filing Language:
`
`Publication Language:
`
`English
`
`English
`
`Priority Data:
`11306096.6
`
`2 September 2011 (02.09.2011)
`
`EP
`
`Applicant (for all designated States except US): HYBRI-
`GENICS SA [FR/FR]; 3/5 Impasse Reille, F-75014 Paris
`(FR).
`
`Inventors; and
`only): COLLAND,
`(for US
`Inventors/Applicants
`Frédéric [FR/FR]; 16 rue du Manoir, F-95380 Puiseux En
`France (FR). GOURDEL, Marie-Edith [FR/FR]; 43 rue
`Grande, F-77176 Savigny Le Temple (FR).
`
`(74)
`
`Agents: BLOT, Philippe ct al.; Cabinct Lavoix, 2, place
`d'Estienne d'Orves, F-75009 Paris (FR).
`
`(81)
`
`Designated States (unless otherwise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
`DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
`HIN, HR, HU, ID,IL, IN, IS, JP, KE, KG, KM, KN, KP,
`KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
`ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NL
`NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
`SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
`TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
`ZW.
`
`(84)
`
`Designated States (unless otherwise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
`UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,TJ,
`TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
`EE, ES, FI, FR, GB, GR, HR, HU,IE,IS, IT, LT, LU, LV,
`MC, MK, MT, NL, NO,PL, PT, RO, RS, SE, SI, SK, SM,
`TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
`ML, MR,NE, SN, TD, TG).
`Published:
`
`with international search report (Art. 21(3))
`
`before the expiration ofthe time limit for amending the
`claims and to be republished in the event of receipt of
`amendments (Rule 48.2(h))
`
`with sequence listing part ofdescription (Rule 5.2(a))
`
`(54) Title: SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7
`
`(PR),
`
`O
`
`a
`
`—a
`N
`
`L+x
`
`a
`
`(CRPR®)
`NN,
`~(CRPR‘)
`
`.
`
`—
`
`5
`LORE
`A
`
`(I)
`
`(57) Abstract: The present invention relates to quinazolin-4-one compounds of formula(I’), their process of preparation and uses
`thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for
`treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
`
`
`
`wo2013/030218A1IIITINMITIMTAIMINUITVRETTTAA
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC
`PROTEASE 7
`
`The present
`
`invention concerns the discovery of new selective and reversible
`
`inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic
`use.
`
`Ubiquitin specific proteases (USP) are cysteines proteases which belong to the
`
`deubiquitinating enzymes (DUBs)family.
`
`10
`
`Deregulation of
`
`the ubiquitin-proteasome system has been implicated in
`
`the
`
`pathogenesis of many human diseases, including cancer (Hoeller et a/. Nat Rev Cancer
`
`2006,
`
`6(10),
`
`776-788), neurodegenerative disorders
`
`(Rubinsztein, Nature 2006,
`
`443(7113), 780-786) and viral diseases (Gao & Luo Can J Physiol Pharmacol! 2006, 84(1),
`5-14). The market success of the proteasome inhibitor Velcade® (bortezomib) for the
`
`15
`
`treatment of multiple myeloma and mantle cell lymphoma has established this system as
`
`a valid target for cancer treatment (Adams, Nat Rev Cancer 2004, 4(5), 349-360). A
`
`promising alternative to targeting the proteasome itself would be to interfere with the
`
`upstream ubiquitin conjugation/deconjugation machinery, to generate more specific, less
`
`toxic anticancer agents.
`
`20
`
`Mono- and polyubiquitination can be reversed by deubiquitinating enzymes, which
`
`specifically cleave the isopeptide bond at the C-terminus of ubiquitin. Ubiquitin specific
`
`proteases and ubiquitin C-terminal hydrolases (UCH) enzymesare the best characterized
`
`members of the DUB family (Komander et al. Nat. Rev. Mol. Cell Biol. 2009, 10(8), 550-
`
`63; Nijman et al. Ceff 2005, 123(5), 773-786). UCHs are thought to cleave small protein
`
`25
`
`substrates preferentially and to be involved principally in the processing and recycling of
`
`ubiquitin, but
`
`their specific functions remain poorly understood. USPs constitute the
`
`largest subfamily of DUBs, with more than 60 members. They remove ubiquitin from
`
`specific protein substrates, thus preventing their targeting to the proteasome or regulating
`
`their subcellular localization and activation (Daviet & Colland, Biochimie 2008, 90(2), 270-
`
`30
`
`83). USPs are emerging as potential targets for pharmacological interference with the
`
`ubiquitin regulation machinery, based on their protease activity and involvement in several
`
`human diseases (Colland, Biochem Soc Trans 2010, 38, 137-43).
`
`USP7 (Ubiquitin Specific Protease 7)/HAUSP (Herpes Associated Ubiquitin
`
`Specific Protease) is a 135 kDa protein of the USP family. USP7 has been shown to
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`2
`
`interact with viral proteins, such as ICPO (Vmw 110), a herpes simplex virus immediate-
`
`early gene stimulating initiation of the viral lytic cycle (Everett et a/., J Virol 73, 1999,
`
`417-426), and EBNA1 (Epstein-Barr Nuclear Antigen-1) (Holowaty ef a/., J Biol Chem
`
`2003, 278, 29987-29994 and 47753-47761). Human proteins, such as p53 and the
`
`major E3 ligase of p53, Mdm2, have also beenidentified as partners and substrates of
`
`USP7 (Cummins ef a/. Nature 2004, 486, Cummins & Vogelstein, Celf Cycle, 2004, 3,
`
`689-692; Li et al. Mo/ Cell 2004, 13, 879-886; Li et al. Nature 2002, 416, 648-653). More
`
`generally USP7 can deubiquitinate different targets, including Mdm2 and p53, and the
`
`net deubiquitination of these latter targets ultimately determines functional p53 levels.
`
`10
`
`Consistent with recent reports, USP7 silencing has also been shownto increase steady-
`
`state p53 levels by promoting Mdm2 degradation. Binding of USP7 to p53 was recently
`
`shownto be regulated by TSPYL5, a protein potentially involved in breast oncogenesis
`
`through a competition with p53 for binding to the same region of USP7 (Epping e¢ a/.,
`
`Nat Cell Biol. 2011, 13(1):102-8). More recently, both upregulation and downregulation
`
`15
`
`of USP7 have been shownto inhibit colon cancercell proliferation in vitro and tumor
`
`growth in vivo, by resulting in constitutively high p53 levels (Becker et a/. Cell Cycle
`
`2008, 7(9),1205-13).
`
`USP7 also alters the level of the p16™*** tumor suppressor through Bmi1/Mel18
`
`stabilization (Maertens et al., Embo J. 2010, 29, 2553-2565). Additional proteins involved
`
`20
`
`in genomic integrity/regulation such as the DNMT1 DNA methylase and the Claspin
`
`adaptor are also stabilized by USP7 (Du et al., Science Signaling 2010, 3(146):ra80;
`
`Faustrup ef a/., J. Celf Biol. 2009,184(1):13-9). Importantly, the abundance of USP7 and
`
`DNMT1, a protein involved in maintaining epigenetic methylation required to silence
`
`genesinvolved in development and cancer, correlates in human colon cancer (Du efal.,
`
`25
`
`Science Signaling, 2010, 3(146):ra80). USP7 has also been shown in human cells to
`
`deubiquitinate the well-known tumor suppressor gene PTEN, which provokesits nuclear
`
`export and henceits inactivation (Song et al/., Nature 2008, 455(7214), 813-7). More
`
`importantly, USP7 overexpression was reported for the first time in prostate cancer and
`
`this overexpression was directly associated with tumour aggressiveness (Song et al.,
`
`30
`
`Nature 2008, 455(7214), 813-7).
`
`USP7 has also been shown in human cells to deubiquitinate FOXO4, which
`
`provokes its nuclear export and hence its
`
`inactivation; consequently the oncogenic
`
`PI3K/PKB signaling pathway was activated (van der Horst ef a/., Nat Cell Biol. 2006, 8,
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`3
`1064-1073) Finally, USP7 plays an important role in p53-mediated cellular responses to
`
`various types of stress, such as DNA damage and oxidative stress (Marchenko ef ai.,
`
`Embo J. 2007 26, 923-934, Meulmeester ef a/., Mol Cell 2005, 18, 565-576., van der
`
`Horst et al., Nat Cell Biol. 2006, 8, 1064-1073).
`Synthetic inhibitors of USP7 protein binding containing the polypeptide portion P'-
`Gly-P*-Ser, where P'
`is a glutamic acid residue or an amino acid with a non polar side
`chain and P® is a glycine residue or an amino acid with non polar side chain, have been
`
`reported (WO2006072048).
`
`The phenotypes associated with USP7 silencing and the known connections
`
`10
`
`between USP7 and essential viral proteins and oncogenic pathways, such as the
`
`p53/Mdm2 and PI3K/PKB pathways,
`
`strongly suggest
`
`that
`
`targeting USP7 with
`
`small-molecule inhibitors may be beneficial in the treatment of cancers and viral diseases
`
`(Sippl et af, Future Oncology 2011, 7, 619-32). Inhibitors against USP7 were recently
`
`reported (Colland et al. Molecular Cancer Therapeutics 2009, 8, 2286-95 and EP
`
`15
`
`1 749 822 and PCT/EP2011/050523.2).
`
`However, to date, no specific and reversible USP7 small molecule inhibitors seem to
`
`have been reported.
`
`According to a first object, the present invention concerns a compoundof formula (I):
`
`(R)
`
`5
`
`O
`
`LL
`
`Re
`
`on’n’)NW) —L*—R®
`
`20
`
`25
`
`30
`
`wherein
`

`
`(1)
`

`
`=
`
`R’, each identical or different, is chosen from the group consisting of halogen, R,
`OR, NRR, CN, CFs, C(O)R, C(O)OR, C(O)NRR’, NOs, (C1-Ce)alkylene-OR, (C,-
`C.)alkylene-NRR’,
`(C,-C.)alkylene-CO.R,
`(C,-C.)alkylene-C(O)NRR’,
`-O-(C;-
`
`C,)alkylene-CO.R, -O-(C;-C.)alkylene-C(O)NRR’, COs-(C;-C,)alkylene-OR, CO.-
`
`C(O)NH-(C,-C,)alkylene-
`C(O)NH-(C,-C,)alkylene-OR,
`(C,-C.)alkylene-NRR’,
`NRR’, OCF, SO2R, SOsH, SO2NRR’, NHSO.R, R™°C=CR", (R1°)(R')C=C(R"")o,
`
`(C,-C,)alkylene-C(O)R, NHC(O)R, or
`
`(C,-C,)alkyl
`
`interrupted by at
`
`least one
`
`heteroatom, preferably chosen among O, N or 8S, preferably O;
`L'is linear or branched (C,-C.)alkylene optionally substituted by one or more of
`
`=O, CN, C(O)R, C(O)OR, or C(O)NRR’, or linear or branched CH,(C,-C,)alkylene,
`
`wherein the later (C,-C,)alkylene is optionally substituted by one or more of
`
`halogen, OR, NRR’ or CF3;
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`4
`X is CR*R’, NR’, aryl, heteroaryl, cycloalkyl or heterocycle, wherein the aryl,
`
`heteroaryl, cycloalkyl or heterocycle is optionally substituted by one or more of
`linear or branched C,-C,(alkyl), halogen, OR, NRR, CN, CFs, C(O)R, C(O)OR or
`
`C(O)NRR’;
`R® is a linear or branched (C,-Cz)alkylene and is linked together with R°=linear or
`branched (C;-C.)alkylene to form with —X-(CR°R*),-N-, to which they are attached,
`
`an heterocycle, preferably a heterocycle having 5 to 7 members, optionally
`substituted by one or more of OR, linear or branched (C,-Cz)alkyl, halogen, NRR,
`CN, CF3, C(O)R, C(O)OR, C(O)NRR’, or =O;
`R®, is chosen amongH and linear or branched (C,-C,)alkyl, (C;-C,)alkylene;
`R®, R*, each identical or different, are chosen in the group consisting of H, linear or
`branched (C,-C,)alkyl, halogen, OR, NRR, CN, CF3, C(O)R, C(O)OR, C(O)NRR’
`
`or =O;
`
`qis0,1,2,30r4
`
`nis 0,1,2o0r3;
`R’ is OR, H, halogen, linear or branched (C,-C.)alkyl-OR, C(O)OR, C(O)NRR’, CN,
`OR®, NRR’ or SR;
`
`iis either O or 1;
`
`A is chosen from the group consisting of:
`
`-
`
`-
`
`-
`
`linear or branched -[C,-C,(alkyl)]o4-C(O)-;
`
`linear or branched -[C,-Ce(alkyl)Jo4-C(O)NH-;
`
`linear or branched -[C,-C,(alkyl)]o-1:SOz2-; or
`
`linear or branched -[C,-C,(alkyl)]o,SO2N-;
`-
`L* is linear or branched (C,;-Cz)alkylene-O or a linear or branched (C;-Cz)alkylene
`optionally interrupted by at least one heteroatom chosen from O, NR or S$ and/or
`
`optionally substituted by: R, OR, NRR’,
`
`(C,-C,)alkyl-OR,
`
`(C,-C,)alkyl-NRR’,
`
`OC(O)R, NHC(O)R, NHC(O)NRR’, CN, G(=NH)NHOR;
`R® is chosen from the group consisting in aryl, heteroaryl, cycloalkyl, heterocycle,
`
`H, wherein the aryl, heteroaryl, cycloalkyl or heterocycle is mono or polycyclic and
`
`is optionally substituted by one or more oflinear or branched (C,-C.)alkyl, halogen,
`NRR, CN, CF;, OR, =O, C(O)R, C(O)OR, NHC(O)R, OC(O)R, linear or branched
`(C2-C,)alkenylene or C(O)NRR’;
`R°
`is chosen from the group consisting of —C(O)R,
`
`-C(O)NHR,
`
`-C(O)OR,
`
`10
`
`15
`
`20
`
`25
`
`30
`
`-C(O)GH2-NRR’, -C(O)-CHs-CH2-CO.R, -C(O)-CH2-SO3H, -C(O)-(CsH4N), -PO3Hz,
`
`35
`
`or their ionized form;
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`

`
`=
`
`=
`
`5
`R"° independently identical or different is chosen from a bond, a linear or branched
`
`(C,-Ce)alkyl;
`R" independently identical or different is chosen from an hydrogen atom, a linear
`
`or branched (C,-Cz)alkyl or an aryl, the alkyl or aryl is optionally substituted by OH,
`
`NH2, C(O)OH or C(O)NH2;
`
`each R and R’,
`
`identical or different, are independently chosen from H, linear or
`
`branched (C,-C.)alkyl, cycloalkyl, aryl, aromatic or non aromatic heterocycle, linear
`
`or branched -(C,-C,)alkyl-aryl or
`
`linear or branched -(C,-C,)alkyl-heterocycle,
`
`wherein the heterocycle is aromatic or non aromatic; optionally substituted or not
`
`10
`
`by OH, CO2H, C(O)NHz, NHz
`
`or
`
`their pharmaceutically acceptable salts or
`
`their optical
`
`isomers,
`
`racemates,
`
`diastereoisomers, enantiomers or tautomers.
`
`The formula (1) of the invention refers to any of the following embodiments or any of their
`
`15
`
`combinations.
`
`Preferably, in compoundof formula (I), R', each identical or different, is chosen from the
`group consisting of linear or branched (C,-Cz)alkyl, halogen, OR, NRR, CN, CFs, C(O)R,
`C(O)OR, C(O)NRR’; NOz;
`(C1-Ce)alkylene-OR,
`(C;-C,)alkylene-NRR’,
`(C,-C,)alkylene-
`
`20
`
`COsR,
`
`(C,-C.)alkylene-C(O)NRR’,
`
`=-O-(C;-Cz)alkylene-COoR,
`
` -O-(C,;-C,)alkylene-
`
`C(O)NRR’, CO2-(C1-Cs)alkylene-OR, CO2-(Ci-Cs)alkylene-NRR’, C(O)NH-(Ci-Cz)alkylene-
`
`OR, C(O)NH-(C,-C,)alkylene-NRR’ or NHC(O)R.
`
`is linear or branched (C;-Cz)alkylene optionally
`Preferably, in compoundof formula (I), L'
`substituted by one or more of =O, CN, C(O)R, C(O)OR, or C(O)NRR’; or linear or
`
`25
`
`branched CH,(C,-C,)alkylene, wherein the later (C,;-C,)alkylene is optionally substituted
`
`by one or more of halogen, OR, NRR’ or CF3.
`
`in compound of formula (I), R? is a linear or branched (C,-Cz)alkylene and is
`Preferably,
`linked together with R®°=linear or branched (C,-Cz)alkylene to form with —X-(CR°R‘*),-N-, to
`
`30
`
`which they are attached, an heterocycle of 5 or 6 members optionally substituted by one
`or more of OR, linear or branched (C;-C.)alkyl, halogen, NRR, CN, CF3, C(O)R, C(O)OR,
`C(O)NRR’, or =O.
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`6
`in compound of formula (I), R’ is OR, OR®, halogen, linear or branched (C,-
`Preferably,
`C.)alkyl-OR, C(O)OR, C(O)NRR’ or CN. More preferably R’ is OR, OR®. More preferably
`R’ is OH or OR’, preferably OH.
`
`R® is chosen from the group consisting in aryl, heteroaryl, cycloalkyl, heterocycle, H,
`
`wherein the aryl, heteroaryl, cycloalkyl or heterocycle is mono or polycyclic and is
`optionally substituted by one or moreof linear or branched (C,-Cz)alkyl, halogen, NRR,
`CN, CF3, OR, C(O)R, C(O)OR, NHC(O)R, OC(O)R or C(O)NRR’.
`
`10
`
`Preferably, in compoundof formula (I), A is chosen from the group consisting of:
`
`-
`
`-
`
`-
`
`-
`
`-C(O)-;
`
`-C(O)NH-;
`
`-SOos-; or
`
`-SON-.
`
`15
`
`20
`
`25
`
`30
`
`35
`
`Preferably, in compound of formula (I), L’ is linear or branched (C;-C,)alkylene optionally
`
`interrupted by at
`
`least one heteroatom chosen from O, NR or S and/or optionally
`
`substituted by
`
`: R, OR, NAR’,
`
`(Ci-Ce)alkyl-OR,
`
`(Ci-Ce)alkyl-NRR’, OC(O)R, NHC(O)R,
`
`NHC(O)NRR’, CN, C(={NH)NHOR.
`
`Preferably, it should be understood that Lz does not represent O-(C;-C.)alkylene.
`
`Preferably, in compoundof formula (I):
`- NR?is directly bonded to at least one of C(O), C(O)N, SOz or SO2N groups; and/or
`
`- i=0, n is 1, 2 or 3 and the CR°R* linked to NR° is C(O); or i=1, A is -C(O)-, C(O)NH, SOz
`
`or SO2N; and/or
`
`-i=0, nis 1, 2 or 3 and the CR°R*linked to NR® is C(O); or i=1, A is -C(O)-, C(O)NH, SO.
`or SO.N, X is CR?R’ or NR* and R® and R’°, identical or different, are linear or branched
`(C,-C.)alkylene and form together with —X-(CR°R’%),-N-,
`to which they are attached, an
`
`heterocycle of 5 to 7 members optionally substituted by one or more of OR, linear or
`branched (C,-C,)alkyl, halogen, NRR, CN, CF3, C(O)R, C(O)OR, C(O)NRR’ and R®, R’,
`eachidentical or different, are chosen in the group consisting of H, linear or branched (C,-
`C,)alkyl, halogen, OR, NRR, CN, CF;, C(O)R, C(O)OR, C(O)NRR’; and/or
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`7
`-i=1 and A is —C(O)-, X is CR®R’ or NR? and R® and R’, identical or different, are linear or
`branched (C,-C.)alkylene and form together with —X-(CR°R‘),-N-,
`to which they are
`
`attached, an heterocycle of 5 to 7 members optionally substituted by one or more of OR,
`linear or branched (C,-C,)alkyl, halogen, NRR, CN, CF3, C(O)R, C(O)OR, C(O)NRR’ and
`R*, R*, each identical or different, are chosen in the group consisting of H,
`linear or
`branched (C,-Cz)alkyl, halogen, OR, NRR, CN, CF3, C(O)R, C(O)OR, C(O)NRR’; and/or
`
`- R', each identical or different, is chosen from the group consisting of linear or branched
`(C,-C,)alkyl, halogen, OR, NRR, CN, CF;, C(O)R, C(O)OR, C(O)NRR’, or NHC(O)R;
`
`10
`
`and/or
`
`- R', each identical or different, is chosen from the group consisting of linear or branched
`
`C,-C,(alkyl), halogen, OH or linear or branched -O-(C,-C,)alkyl; and or
`
`15
`
`- R', each identical or different, is chosen from the group consisting of halogen orlinear or
`
`branched -O-(C,-C,)alkyl; and/or
`
`-qis 0,
`
`1 or 2; and/or
`
`20
`
`identical or different, are linear or branched (C,-
`- X is CR?R’ or NR* and R® and R*,
`C.)alkylene and form together with —X-(CR°R*),-N-,
`to which they are attached, an
`
`heterocycle of 5 to 7 members optionally substituted by one or more of OR, linear or
`branched (C,-C.)alkyl, halogen, NRR, CN, CF3, C(O)R, C(O)OR, or C(O)NRR’.
`Preferably, the heterocycle formed by —XR*-(CR°R’),-NR°- is a non aromatic heterocycle;
`
`25
`
`and/or
`
`linear or
`- R®, R*, each identical or different, are chosen in the group consisting of H,
`branched (C,-C,)alkyl, halogen, =O, OR, NRR, CN, CF;, C(O)R, C(O)OR or C(O)NRR’;
`
`and/or
`
`30
`
`- R®, R*, each identical or different, are chosen in the group consisting of H, -O-(C,-
`C.)alkyl, OH and =O. Preferably, R°, R*, each identical or different, are chosen in the
`
`group consisting of H and OH; and/or
`
`35
`
`- X is CR°R’, or aryl and R’ is OR, OR’, linear or branched (C;-C.)alkyl-OR, halogen,
`C(O)OH, NRR’, C(O)NHz2or SR . Preferably, X is CR°R’, or aryl and R’ is OR, OR®, NRR’
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`8
`or SR. More preferably, R’ is OH or OR’®, preferably OH. R® being as defined above;
`
`and/or
`
`- X is an aryl, preferably phenyl and/or
`
`- L'
`
`is linear or branched C,-C,.(alkylene) optionally substituted by one or more =O or is
`
`linear or branched CH2-C,-C,(alkylene), wherein the later alkylene is optionally substituted
`
`by one or more —OH; and/or
`
`10
`
`- L?
`
`is
`
`linear or branched C,-C,(alkylene)-O or
`
`linear or branched C,-C,(alkylene)
`
`optionally interrupted by at least one heteroatom chosen from O or S and/or optionally
`
`(C,-C.)alkyl-NRR’,
`(C,-C,)alkyl-OR,
`: R, OR, NRR’,
`substituted by one or more of
`OC(O)R, NHC(O)R, NHC(O)NRR’, CN, C(=NH)NHOR;. More preferably L’
`is linear or
`
`branched C,-C,(alkylene) or linear or branched -[C,-C,(alkylene)]-O-; and/or
`
`15
`
`- R® is chosen from the group consisting in aryl, heteroaryl, cycloalkyl or H, wherein the
`
`aryl, heteroaryl or cycloalkyl is optionally substituted by halogen, linear or branched O-(C,-
`
`Ce)alkyl; and/or
`
`20
`
`- R® is chosen from the group consisting in phenyl, thiophenyl, cyclopentyl and H, wherein
`
`the phenyl is optionally substituted by halogen, linear or branched O-(C,-Caz)alkyl.
`
`In one embodiment, in the compoundof formula (I), X is CR?R’ or NR? and R* and R° form
`together with —X-(CR°R’*),-N- to which they are attached an heterocycle of 5 to 7 members
`optionally substituted by one or more OH. Preferably, in this particular embodiment, n is 0,
`1 or 2 and/or X is CR’*R’ wherein R’ is OR, OR’, linear or branched (C,-C,)alkyl-OR,
`halogen, C(O)OH, C(O)NH2, NRR’ or SR, and/or L'
`is (CH2), wherein k is
`1 or 2,
`preferably k is 1, -C(O)-, -CH»-CH(OH)- or -CH.-C(O)-. Preferably R’ is OR, OR®, NRR’ or
`SR. Morepreferably, R’ is OH or OR’, preferably OH. R® being as defined above.
`
`In another embodiment, in the compoundof formula (I), X is aryl, heteroaryl, cycloalkyl or
`
`heterocycle, wherein the aryl, heteroaryl, cycloalkyl or heterocycle is optionally substituted
`by one or more oflinear or branched C,-C,(alkyl), halogen, OR, NRR, CN, CF3, C(O)R,
`C(O)OR or C(O)NRR’, preferably X is aryl and R® is H or linear or branched C,-C,(alkyl),
`preferably H. Preferably,in this particular embodiment, n is 0 and/or X is aryl and/or L' is —
`
`CH2-CH(OH)-.
`
`25
`
`30
`
`35
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`9
`According to a particular embodiment, compoundsof the invention may beof the following
`
`formula (la)
`
`wherein
`
`(R’),
`
`oO
`
`N~
`2
`
`(CR’)
`
`p
`
`ym wk
`~(CRPR*)7 SS
`
`L2-R®
`
`(la)
`
`= R’,q, L’, L?, R° and R’ are as defined in formula(1);
`» X’is CR’ orN;
`
`=
`
`nis 0,1 or 2;
`
`= pis 1,2or3;

`R®, R* and R®, each identical or different, are chosen in the group consisting of H,
`linear or branched (C,-Ce)alkyl, halogen, OH, -O-(C,-C.)alkyl, NRR, CN, CFs, OR,
`C(O)R, C(O)OR or C(O)NRR’.
`Preferably in the compound of formula (la), R®, R* and R®, each identical or different, are
`
`chosen in the group consisting of H or OH; and/or p is 1 or 2.
`
`Preferably in compoundof formula (la)
`
`oe SO Le
`
`~(CRPR’),a
`
`oSas
`a
`
`R®)
`
`L\-
`R’
`
`< \
`or
`
`)
`
`1 or 2 preferably
`tis O,
`wherein R’ is OR, halogen, linear or branched (C,;-C,)alkyl-OR, C(O)OR, C(O)NRR’, CN,
`OR®, NRR’ or SR, more preferably OR, OR®, NRR’ or SR, preferably OH or OR’, p is 1 or
`2 and R°®is chosenin the group consisting of H or OH.
`
`According to a particular embodiment, compoundsof the invention may beof the following
`
`formula (la)
`
`1
`(R ),
`
`(CR*R"),
`O a oN
`L-x'
`LN X
`Ne
`(CRPR*) 7
`
`6
`
`>
`LR
`
`(la)
`
`10
`
`15
`
`20
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`wherein
`
`10
`
`= R’,q, L’, L?, R° and R’ are as defined in formula(1);
`» X’is CR’ orN;
`
`=
`
`nis 0,1 or 2;
`
`= pis1,2or3;

`R®, R*, R® and R®, each identical or different, are chosen in the group consisting of
`H, linear or branched (C,-Cez)alkyl, halogen, OH, -O-(C,-C,)alkyl, NRR, CN, CFs,
`OR, C(O)R, C(O)OR or C(O)NRR’.
`Preferably in the compound of formula (la), R®, R*, R® and R®’, each identical or different,
`
`10
`
`are chosenin the group consisting of H or OH; and/or p is 1 or 2.
`
`Preferably in compoundof formula (la)
`
`PaOe
`
`.
`*R)
`N-
`—_xX
`“(CRR*)~ aR’
`Is
`
`R®),
`N-
`
`R’),
`N—
`
`=
`
`R
`
`8
`R)
`
`N
`|
`
`or
`
`ph DB vo
`
`R°)
`ae
`\
`
`\e
`
`R®),
`
`N—
`
`N—
`
`_
`
`AD
`LO OS
`x» = oe
`
`1 or 2 preferably
`is 0,
`wherein R’ is OR, halogen, linear or branched (C;-Cz)alkyl-OR, C(O)OR, C(O)NRR’, CN,
`OR®, NRR’ or SR, more preferably OR, OR®, NRR’ or SR, preferably OH or OR’, p is 1 or
`2 and R®is chosenin the group consisting of H or OH.
`
`Jt
`
`a
`
`According to a particular embodiment, compoundsof the invention may beof the following
`
`formula (Ib)
`
`wherein
`
`(R')
`
`q
`
`r oR
`it
`yex NX
`2
`
`(Ib)
`
`= R',q, L’ and R® are as defined for compoundsof formula(I);
`
`= X is aryl, heteroaryl, cycloalkyl or heterocycle, wherein the aryl, heteroaryl,
`
`linear or
`cycloalkyl or heterocycle is optionally substituted by one or more of
`branched C,-C,(alkyl), halogen, OH, linear or branched -O-(C,-C,)alkyl, NRR, CN,
`CFs, OR, C(O)R, C(O)OR or C(O)NRR’;
`R?’is H or linear or branched (C,-Cs)alkyl;
`

`
`15
`
`20
`
`25
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`11
`L'is linear or branched (C,-C,)alkyl substituted by one or more OH.
`
`=
`
`Preferably in compoundof formula (Ib), X is phenyl.
`Preferably in compound of formula (Ib), R° is H.
`
`According to a particular embodiment, compoundsof the invention may be of the following
`
`formula (I’)
`
`wherein
`
`(R’),
`
`O
`
`xy
`
`Zz
`N
`
`(CR®R®)
`
`p
`
`ay Ng
`~(CR°R*)7
`
`t= R®
`
`(I')
`
`10
`
`15
`
`= R’,q, L', A, L’, R, R’ and R® are as defined in formula(I);
`= X’is CR’;
`= R’is OR, halogen, linear or branched (C,-Cgs)alkyl-OR, C(O)OR, C(O)NRR’, CN,
`OR®, NRR’ or SR, more preferably OR, OR®, NRA’ or SR;
`R’°is as defined in formula (I);
`
`=
`
`=
`
`nis 0,1 or 2;
`
`= pis1,2or3;
`=
`R®, R*, R® and R®’, each identical or different, are chosen in the group consisting of
`H, linear or branched (C,-C,)alkyl, halogen, OH, -O-(C,-C,)alkyl, NRR, CN, CFs,
`OR, C(O)R, C(O)OR or C(O)NRR’.
`
`20
`
`Preferably, in compoundof formula (I), Ais chosen from the group consisting of:
`
`-
`
`-
`
`-
`
`-
`
`-C(O)-;
`
` -C(O)NH-;
`
` -SObs-; or
`
`-SO2N-.
`
`25
`
`30
`
`Preferably, in the compoundsof formula (I’), R°®, R*, R° and R®’, each identical or different,
`
`are chosenin the group consisting of H or OH, and/or p is 1 or 2.
`Preferably,
`in the compounds of formula (I’) R’ is OR, halogen, linear or branched (C,-
`
`C.)alkyl-OR, C(O)OR, C(O)NRR’, CN, more preferably OH.
`
`Preferably, in the compounds of formula (I’) R’ is OR, OR®, NRR’ or SR, more preferably
`R’ is OR, OR’, preferably OH or OR’, for example OH.
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`12
`Preferably, in the compounds of formula (I’) p+n = 4; more preferably p is 2 andnis 2.
`eer”,
`“(CRPR’)7 aR?
`
`Preferably in compoundof formula (I’)
`Preferably, in the compounds of formula (I’) L' is CHp.
`
`Preferably, in the compoundsof formula (I’) p is 2 and n is 2, R’ is OR, OR®, NRR’ or SR,
`more preferably R’ is OR, OR®, preferably OH or OR’, for example OH.
`
`Preferably, in the of formula (I’) p is 2 andnis 2, and L' is CHs,
`
`10
`
`is CH: and R’ is OR, OR®, NRR’ or SR,
`in the compounds of formula (I’) L'
`Preferably,
`more preferably R’ is OR, OR’®, preferably OH or OR’, for example OH.
`
`is CH2, R’ is R’ is OR,
`in the compoundsof formula (I’) p is 2 and n is 2, L'
`Preferably,
`OR®, NRR’ or SR, more preferably R’ is OR, OR’®, preferably OH or OR’, for example OH.
`
`According to a particular embodiment,
`
`in the compounds of formula (I’) A is C=O, the
`
`compound is thus of the following formula (la’)
`
`(R')
`
`q
`
`T
`N
`2
`
`N
`
`(CR*®R®)
`1 a NN LER®
`LLEX'
`3g
`4 NX
`(CR R Mn
`O
`
`15
`
`20
`
`(la’)
`wherein R', q, L', n, p, X’, R®, R*, R®, R®, L’, R® and R’ are as defined in formula(I’).
`Pace
`(GRR),
`
`7
`
`is R
`
`.
`
`Preferably in compound of formula (la’)
`
`~ 354,
`
`According to a specific embodiment, the invention relates to compounds of formula (I) as
`
`defined above with the exception of the following compound:
`- qis 0, L' is CH2, X-(CR°R*),-NR° forms a piperidine, X is CR*R’ and R’ is OH, iis 1, Ais
`
`25
`
`C=O, L? is CoH, and R°is
`
`2
`
`CH, .
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`13
`is CHs, X-(CR°R*),-NR° forms a piperidine, X is CR?R’
`-qis 1, R'is Cl at position 7, L'
`and R’ is OH, iis 1, Ais C=O, L?R® is CH(CH2CHs)>.
`
`According to a specific embodiment, the compounds of formula (lI) are chosen from:
`
`3-({4-hydroxy- 1-[3-(2-methoxyphenyl)propanoyl]piperidin-4-yl}methyl)-3,4-
`
`dihydroquinazolin-4-one
`
`7-chloro-3-{[1 -(2-ethyloutanoyl)-4-hydroxypiperidin-4-yl]methyl}-3 ,4-dihydroquinazolin-4-
`one
`
`3-({1-[2-(3-fluorophenoxy)acetyl]-4-hydroxypiperidin-4-yl}methyl)-3,4-dinydroquinazolin-4-
`one
`
`10
`
`3-{[4-hydroxy-1-(2-methylpropanoyl)piperidin-4-yl]methyl}-6 ,7-dimethoxy-3,4-
`
`dihydroquinazolin-4-one
`
`3-{[4-hydroxy-1 -(2-methylpropanoyl) piperidin-4-yl]methyl}-3 ,4-dihydroquinazolin-4-one
`
`4-hydroxy- 1-[2-methyl-3-(thiophen-2-yl)propanoyl]piperidin-4-yl}methyl)-3 ,4-
`
`15
`
`dihydroquinazolin-4-one
`
`7-chloro-3-{[1 -(3-cyclopentylpropanoyl)-4-hydroxypiperidin-4-yl]methyl}-3,4-
`
`dihydroquinazolin-4-one
`
`3-{[1-(3-cyclopentylpropanoyl)-4-hydroxypiperidin-4-yl]Jmethyl}-3,4-dihydroquinazolin-4-
`one
`
`20
`
`7-chloro-3-{[4-hydroxy-1 -(3-phenylpropanoyl)piperidin-4-yl]methyl}-3,4-dihydroquinazolin-
`
`4-one
`
`3-{[4-hydroxy-1-(3-phenylpropanoyl)piperidin-4-yl]methyl}-3,4-dihydroquinazolin-4-one
`
`7-chloro-3-({4-hydroxy- 1-[2-methyl-3-(thiophen-2-yl)propanoyl]piperidin-4-yl} methyl)-3,4-
`
`dihydroquinazolin-4-one
`
`25
`
`3-({4-hydroxy- 1-[3-(thiophen-2-yl)propanoyl]piperidin-4-yl}methyl)-3,4-dihydroquinazolin-4-
`one
`
`3-{[1-(2-benzylpropanoyl)-4-hydroxypiperidin-4-yl]methy]}-3,4-dihydroquinazolin-4-one
`
`3-{[1-(2-benzylpropanoyl)-4-hydroxypiperidin-4-yl]methy]}-7-chloro-3,4-dihydroquinazolin-
`
`4-one,
`
`30
`
`or
`
`their pharmaceutically acceptable
`
`salts or
`
`their optical
`
`isomers,
`
`racemates,
`
`diastereoisomers, enantiomers or tautomers.
`
`As used hereaboveor hereafter:
`
`"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched
`
`35
`
`having 1
`
`to 6 carbon atoms in the chain. "Branched" means that one or more lower alkyl
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`14
`groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl
`
`groups include methyl, ethyl, n-propyl, -propyl, n-butyl, Hbutyl, n-pentyl, 3-pentyl.
`
`As used herein, the term “cycloalkyl” refers a non aromatic monocyclic or multicyclic
`
`hydrocarbon ring of 3 to 10 carbon atoms formed by the removal of one hydrogen atom. A
`
`designation such as "C.-C; cycloalkyl" refers to a cycloalkyl radical containing from 5 to 7
`
`carbon atoms. Examplesinclude cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
`
`adamantyl, etc. as well as the systems formed by their condensation or by the condensation
`
`with a phenyl group.
`
`"Alken" or alkenyl means an aliphatic hydrocarbon group containing a carbon-carbon
`
`10
`
`double bond and which maybestraight or branched having 2 to 6 carbon atoms in the
`
`chain. Preferred alkenyl groups have 2 to 6 carbon atoms in the chain; and more
`
`preferably about 2 to 4 carbon atoms in the chain. Exemplary alkenyl groups include
`
`ethenyl, propenyl, n-butenyl, H-butenyl, 3-methylbut-2-enyl, n-pentenyl.
`
`"Halogen atom" refers to fluorine, chlorine, bromine or
`
`iodine atom; preferably
`
`15
`
`fluorine and chlorine atom.
`
`"Aryl" means an aromatic monocyclic or multicyclic hydrocarbon ring system of 6 to
`
`14 carbon atoms, preferably of 6 to 10 carbon atoms, substituted or not. Exemplary aryl
`
`groups include phenyl or naphthyl.
`
`As used herein, the terms “heterocycle” or “heterocyclic” refer to a saturated, partially
`
`20
`
`unsaturated or unsaturated, non aromatic stable 3 to 14, preferably 5 to 10-membered mono,
`
`bi or multicyclic rings wherein at least one memberof the ring is a hetero atom, substituted or
`
`not. Typically, heteroatoms include, but are notlimited to, oxygen, nitrogen, sulfur, selenium,
`
`and phosphorus atoms. Preferable heteroatoms are oxygen, nitrogen and sulfur.
`
`Suitable heterocycles are also disclosed in The Handbook of Chemistry and Physics,
`76" Edition, CRC Press, Inc., 1995-1996, p. 2-25 to 2-26, the disclosure of which is hereby
`
`25
`
`incorporated by reference. Example of aromatic heterocycle is thiophenyl.
`
`Preferred non aromatic heterocyclic include, but are not
`
`limited to pyrrolidinyl,
`
`pyrazolidinyl,
`
`imidazolidinyl,
`
`oxiranyl,
`
`tetrahydrofuranyl,
`
`dioxolanyl,
`
`tetrahydro-pyranyl,
`
`dioxanyl, dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl,
`
`imidazolinyl, pyrrolinyl,
`
`30
`
`pyrazolinyl,
`
`thiazolidinyl,
`
`tetrahydrothiopyranyl, dithianyl,
`
`thiomorpholinyl, dihydro-pyranyl,
`
`tetrahydropyranyl, dihydropyranyl,
`
`tetrahydro-pyridyl, dihydropyridyl,
`
`tetrahydropyrinidinyl,
`
`dihydrothiopyranyl, azepanyl, as well as the fused systems resulting from the condensation
`
`with a phenyl group, each substituted or not.
`
`As used herein, the term “heteroaryl” or aromatic heterocycles refers to a 5 to 14,
`
`35
`
`preferably 5 to 10-membered aromatic hetero, mono-, bi- or multicyclic ring. Examples include
`
`pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl,
`
`

`

`WO 2013/030218
`
`PCT/EP2012/066741
`
`imidazolyl,
`
`thienyl,
`
`thiazolyl,
`
`nenzothiazolyl
`
`furanyl,
`
`benzofuranyl,
`
`1,2,4-thiadiazolyl,
`
`isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl,
`
`benzimidazolyl, isoxazolyl, pyridyl-N-oxide , as well as the fused systems resulting from the
`
`condensation with a phenyl group.
`
`"Alkyl", "cycloalkyl", "aryl", "heteroaryl", "heterocycle" and the likes refers also to the
`
`corresponding “alkylene”, "cycloalkylene", "arylene", "heteroarylene", "heterocyclene” and the
`
`likes which are formed by the removal of two hydrogen atoms. Alkyl and alkylene are used
`
`herein interchangeably.
`
`10
`
`As used herein, the term "patient" refers to either an animal, such as a valuable animal
`
`for breeding, company or preservation purposes, or preferably a human or a humanchild,
`
`which is affl

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket